Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mingrui Du

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
International Journal of Molecular Sciences|September 27, 2025
Inhibition of the HMGB1-RAGE Axis Attenuates Microglial Inflammation and Ameliorates Hypoxia-Induced Cognitive ImpairmentChenlin Liu, Haowei Zhang, Ruili Guan, et al.
Biochemical Pharmacology|June 14, 2024
EYA4 reduces chemosensitivity of osteosarcoma to doxorubicin through DNA damage repairWei Heng, Tianfu Wang, Feilong Wei, et al.
Frontiers in Physiology|September 19, 2022
Physical exercise improved muscle strength and pain on neck and shoulder in military pilotsWei Heng, Feilong Wei, Zhisheng Liu, et al.
Iscience|July 18, 2025
CircYAP1 inhibits osteosarcoma progression through the miR-135b-5p/FRK axisMingrui Du, Xuesan Zhang, Menglin Cong, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 23, 2022
Genome-wide CRISPR screen identified Rad18 as a determinant of doxorubicin sensitivity in osteosarcomaMingrui Du, Jintao Gu, Chenlin Liu, et al.
Annals of Translational Medicine|November 4, 2021
LncRNA <i>FTX</i> promotes the malignant progression of colorectal cancer by regulating the miR-214-5p-JAG1 axisLuxiang Pan, Mingrui Du, Haixia Liu, et al.
Journal of Nanobiotechnology|January 4, 2025
Inhibition of METTL14 overcomes CDK4/6 inhibitor resistance driven by METTL14-m6A-E2F1-axis in ERα-positive breast cancerChenlin Liu, Dong Fan, Jiahui Sun, et al.
Frontiers in Pharmacology|September 5, 2022
Kill two birds with one stone: Engineered exosome-mediated delivery of cholesterol modified YY1-siRNA enhances chemoradiotherapy sensitivity of glioblastomaXiao Liu, Zhengcong Cao, Nannan Liu, et al.
Journal of Nanobiotechnology|January 8, 2026
Targeting TRIM25 as a therapeutic strategy to enhance ferroptosis in glioblastoma cellsMaorong Zhu, Yuxin Wu, Huihui Ou, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
International Journal of Molecular Sciences|September 27, 2025
Inhibition of the HMGB1-RAGE Axis Attenuates Microglial Inflammation and Ameliorates Hypoxia-Induced Cognitive ImpairmentChenlin Liu, Haowei Zhang, Ruili Guan, et al.
Biochemical Pharmacology|June 14, 2024
EYA4 reduces chemosensitivity of osteosarcoma to doxorubicin through DNA damage repairWei Heng, Tianfu Wang, Feilong Wei, et al.
Frontiers in Physiology|September 19, 2022
Physical exercise improved muscle strength and pain on neck and shoulder in military pilotsWei Heng, Feilong Wei, Zhisheng Liu, et al.
Iscience|July 18, 2025
CircYAP1 inhibits osteosarcoma progression through the miR-135b-5p/FRK axisMingrui Du, Xuesan Zhang, Menglin Cong, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 23, 2022
Genome-wide CRISPR screen identified Rad18 as a determinant of doxorubicin sensitivity in osteosarcomaMingrui Du, Jintao Gu, Chenlin Liu, et al.
Annals of Translational Medicine|November 4, 2021
LncRNA <i>FTX</i> promotes the malignant progression of colorectal cancer by regulating the miR-214-5p-JAG1 axisLuxiang Pan, Mingrui Du, Haixia Liu, et al.
Journal of Nanobiotechnology|January 4, 2025
Inhibition of METTL14 overcomes CDK4/6 inhibitor resistance driven by METTL14-m6A-E2F1-axis in ERα-positive breast cancerChenlin Liu, Dong Fan, Jiahui Sun, et al.
Frontiers in Pharmacology|September 5, 2022
Kill two birds with one stone: Engineered exosome-mediated delivery of cholesterol modified YY1-siRNA enhances chemoradiotherapy sensitivity of glioblastomaXiao Liu, Zhengcong Cao, Nannan Liu, et al.
Journal of Nanobiotechnology|January 8, 2026
Targeting TRIM25 as a therapeutic strategy to enhance ferroptosis in glioblastoma cellsMaorong Zhu, Yuxin Wu, Huihui Ou, et al.
Pageof 2